PEGylated drug delivery systems in the pharmaceutical field: past, present and future perspective.
Cancer
PEGylation
conjugate
diabetes
hemophilia
therapy
Journal
Drug development and industrial pharmacy
ISSN: 1520-5762
Titre abrégé: Drug Dev Ind Pharm
Pays: England
ID NLM: 7802620
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
pubmed:
14
7
2022
medline:
16
8
2022
entrez:
13
7
2022
Statut:
ppublish
Résumé
Target-site drug delivery systems are gaining interest in the pharmaceutical field due to their great advantages, such as higher drug dosing capacity and better bioavailability. However, some existing problems need to be overcome. An example, is the interaction between blood proteins and drug delivery systems. A potent candidate to approach the mentioned problem is based on polyethylene glycol (PEG) surface modifications. This polymer acts as a protector against the external possible interactions with other compounds, making targeted delivery possible. Diseases such as cancer, diabetes, hemophilia and pain treatment can benefit from these new systems. This review aims to give an overview of drug delivery systems based on PEGylation as surface modification as the pharmaceutical approach. Moreover, a deeper insight into the properties of PEG and its advantages is given, as well as a brief overview of present therapies based on this technology.
Identifiants
pubmed: 35822253
doi: 10.1080/03639045.2022.2101062
doi:
Substances chimiques
Pharmaceutical Preparations
0
Polyethylene Glycols
3WJQ0SDW1A
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM